CClinicalTrials.gg
Status unknownNCT00173654Updated Dec 21, 2005

Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency

An observational study in Pseudohermaphroditism, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-12-21.

Sponsored by National Taiwan University Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2005), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Defined population
Time perspective
Other
Enrollment
20
Ages
0 Years and older
Sex
All
01

Study summary

To disclose the molecular pathology of our 3 families with 17βHSD3 deficiency.

Read the detailed description

17βhydroxysteroid dehydrogenase 3 (17βHSD3) deficiency is a rare cause of male pseudohermaphroditism. The incidence is reported to be 1: 147,000 in the Netherlands. Fewer than one hundred affected 46, XY males were reported in the literature, and no such case has been reported in Taiwan before. The 46, XY patients have ambiguious or complete female external genitalia. They are mostly unrecognized at birth and reared as female. They often draw medical attention when they receive operation for inguinal hernia or during puberty, clitoromegaly and musculization were noticed. However, the homozygous or compound heterozygous genetic females are asymptomatic. The 17βHSD3 catalyze the conversion of androstenedione to testosterone, the last step in the synthesis of testosterone. Therefore, the serum levels of androstenedione are elevated and testosterone or dihydrotestosterone are in the low range in these affected 46, XY individuals. The clinical diagnosis is made by HCG stimulation test, because androstenedione-to-testosterone ratio is abnormally elevated in these patients. But the molecular basis of 17βHSD3 deficiency was not determined till recent decade.

The HSD17B3 gene was elucidated in 1994, and composed of 11 exons. Several missence mutation and splice mutation were identified. But the precise action and tissue distribution of 17βHSD3 still need to be clarified. The Wölffian ducts virilze normally in the embryonic stage and the serum concentration of testosterone achieve to the normal range in the pubertal stage. The exact mechanism is not understood clearly and peripheral conversion under other isozymes was suggested in some studies.

The purpose of this study is to disclose the molecular pathology of our 3 families with 17βHSD3 deficiency.

02

Conditions studied

  • Pseudohermaphroditism
03

In context

Disorders of Sex Development

21 studies on the registry are indexed under Disorders of Sex Development; 7 are open to participants now.

This study's enrollment of 20 is below the median of 210 across 12 observational studies indexed under Disorders of Sex Development.

Browse Disorders of Sex Development studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with 17β-hydroxysteroid dehydrogenase 3 deficiency and their family
05

Study design

Observational model
Defined population
Time perspective
Other
Enrollment
20 participants

Interventions

  • Procedureblood drawing
06

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00173654
Lead sponsor
National Taiwan University Hospital
First posted
Sep 15, 2005
Start date
Aug 2005
Completion
Aug 2006
Last update
Dec 21, 2005

Study contacts

Yi-Ching Tung, MD
Contact
dtped004@yahoo.com.tw
886-2-23123456 ext. 5130
Yi-Ching Tung, MD
principal investigator · National Taiwan University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion